Back to results
US 2016/0355600 A1Published application
Trispecific antibodies
AssigneeXencor, Inc.
InventorsGregory Moore, John Desjarlais, Seung Chu, Sung-Hyung Lee
Life of this patent
Estimating the term…
Abstract
The invention provides trispecific antibodies that co-engage CD3, CD8 and a tumor target antigen.
Claims10
-14. (canceled)
A trispecific antibody comprising:
- a) a first monomer comprising:
- i) a first heavy chain comprising a first variant Fc domain and a first variable heavy domain;
- ii) a first scFv domain;
- and
- b) a second monomer comprising:
- i) a second heavy chain comprising a second variant Fc domain and said first variable heavy domain;
- ii) a second scFv domain;
- and
- c) a light chain comprising a constant light domain and a variable light domain;
- wherein said first variable heavy domain and said variable light domain forms a first antigen binding domain that binds a first antigen, said first scFv domain forms a second antigen binding domain that binds a second antigen, and said second scFv domain forms a third antigen binding domain that binds a third antigen, and one of said binding domains binds CD8 and has a variable region comprising a variable region selected from the group consisting of a variable region comprising a variable heavy domain having the sequence of OKT8 H1 and a variable light domain having the sequence LL a variable region comprising a variable heavy domain having the sequence of OKT8 H2 and a variable light domain having the sequence LL a variable region comprising a variable heavy domain having the sequence of OKT8 H1 and a variable light domain having the sequence L2 and a variable region comprising a variable heavy domain having the sequence of 51.1 H1 and a variable light domain having the sequence L1.
7 more elements
-53. (canceled)
-102. (canceled)
Dependencies are inferred from the claim text.